Koerber, Stefan A.
Finck, R.
Dendl, K.
Uhl, M.
Lindner, T.
Kratochwil, C.
Röhrich, M.
Rathke, H.
Ungerechts, G.
Adeberg, S.
Herfarth, K.
Jaeger, D.
Debus, J.
Haberkorn, U.
Giesel, F. L.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 13 January 2021
Accepted: 18 April 2021
First Online: 21 May 2021
Declarations
:
: This retrospective study was approved by the local institutional review board.
: Patients provided written informed consent.
: Patients provided written informed consent.
: SAK reports grants from Viewray Inc., outside the submitted work. CK, TL, UH, and FLG have a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. CK, TL, UH, and FLG also have shares of a consultancy group for iTheranostics. FLG is a medical advisor for ABX Advanced Biochemical Compound, Sofie Biosciences, and Telix Pharmaceuticals. SA received grants from Accuray International Sari, Merck Serono GmbH, AstraZeneca GmbH, and Novocure GmbH outside the submitted work. S.A. reports on Novocure GmbH, Actinium Pharmaceuticals, and Telix Pharmaceuticals shareholding. JD reports grants from Viewray Inc., grants from CRI (the Clinical Research Institute GmbH), grants from Accuray International Sari, grants from RaySearch Laboratories AB, grants from Vision RT Limited, grants from Merck Serono GmbH, grants from Astellas Pharma GmbH, grants from AstraZeneca GmbH, grants from Siemens Healthcare GmbH, grants from Solution Akademie GmbH, grants from Egomed PLC Surrey Research Park, grants from Quintiles GmbH, grants from Pharmaceutical Research Associates GmbH, grants from Boehringer Ingelheim Pharma GmbH&CoKG, grants from PTW-Freiburg Dr. Pychlau GmbH, and grants from Nanobiotix S.A, outside the submitted work.